Cantargia AB (publ) (CANTA) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Many thanks and welcome everybody to today's interim report of our first quarter 2025. On this next slide, you see our safe harbour statement, which of course its main effect is to make everybody aware that any forward-looking statements that we make should be taken with great care and not relied on or taken as guarantees of future performance. So as we've just introduced, I'm Damian Marron. I'm the interim chief executive officer. I'll be taking the first few slides for you and then handing over to Maureen Lynn Jensen, our chief medical officer. And we also have Patrick Remblad, our chief financial officer, who will take us through the financial section of today's presentation. So it's been a busy first quarter and actually a busy few weeks since the end of that quarter as well. So just quickly, here are the significant events that occurred in the first quarter of 2025. I was appointed as the interim CEO following the resignation of Joram Furstberg, our longstanding prior CEO. We then presented promising phase one data from our CAN10 first multi-dose cohort, as well as feedback from the FDA and the clinical experts. We finished recruitment in the randomized phase two TRIAD4 study in triple negative breast cancer with Nadionolimab, and we enrolled the first patient in a new investigator-initiated study of nadionolamab in leukemia that is taking place in the US. And we published two abstracts on IL-1 RAP-ADC and on nadionolamab's potential to reduce chemotherapy-induced neuropathy. We announced they will be presented at AACR, which has just taken place. Significant results since the reporting period are obviously the appointment of Morton Lindjensen as Chief Medical Officer, and he will be speaking with you today. We selected treatment-resistant atopic dermatitis as o...